PPARG and type 2 diabetes mellitus: Thiazolidinedione, a target drug of PPARγ, has potent insulin-sensitizing effects and is used to treat T2DM, but the drug will produce side effects such as weight gain, liver damage, and cardiovascular risk and is gradually declining in clinical use [13, 14].